Sarepta Therapeutics, Inc. (SRPT)
Nasdaq · Healthcare · Biotechnology
$17.49−0.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.8B
- Forward P/E
- 7.3
- 52-week range
- $14.68 – $25.32
- 52-week change
- −24.31%
- EPS (trailing)
- −$1.57
- Analyst rating
- 2.8 Hold
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $2.2B (+15.57%)
- Net income
- −$713M
- Operating margin
- −31.8%
- Diluted EPS
- −$7.13
- Free cash flow
- −$307M
From the company’s annual report on SEC EDGAR.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F.
Headquarters: Cambridge, United States · 835 employees · sarepta.com